PCVX - Vaxcyte, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.73
+0.96 (+3.34%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close28.77
Open28.88
Bid26.18 x 800
Ask35.34 x 800
Day's Range28.67 - 30.48
52 Week Range17.80 - 36.50
Volume97,724
Avg. Volume379,683
Market Cap1.508B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

      FOSTER CITY, Calif., June 16, 2020 -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines.

    • MarketWatch

      Vaccine maker Vaxcyte's shares soar 22% in trading debut

      Shares of Vaxcyte Inc. soared 22% in their trading debut Friday, after the company's IPO priced at the top end of its price range, and was upsized to 15.6 million shares from earlier plans to sell just 14 million. The company raised $249.6 million. The shares are trading on Nasdaq later Friday under the ticker symbol "PCVX." BofA Securities, Jefferies and Evercore ISI were lead underwriters on the deal with Cantor and Needham acting as co-managers. "We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide," says the prospectus. Proceeds of the deal will be used top fund clinical development and for general corporate purposes.

    • MarketWatch

      Vaccine maker Vaxcyte upsizes IPO and prices at top end of range

      Vaxcyte Inc. priced its initial public offering late Thursday at $16 a share, the top end of its price range, and upzied the deal to 15.6 million shares from earlier plans to sell just 14 million. The company raised $249.6 million. The shares will start trading on Nasdaq later Friday under the ticker symbol "PCVX." BofA Securities, Jefferies and Evercore ISI were lead underwriters on the deal with Cantor and Needham acting as co-managers. "We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide," says the prospectus. Proceeds of the deal will be used top fund clinical development and for general corporate purposes.

    • GlobeNewswire

      Vaxcyte Announces Pricing of Upsized Initial Public Offering

      FOSTER CITY, Calif., June 11, 2020 -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to.

    • GlobeNewswire

      Vaxcyte Appoints Halley E. Gilbert to Board of Directors

      FOSTER CITY, Calif., June 03, 2020 -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and.

    • GlobeNewswire

      SutroVax Announces Name Change to Vaxcyte

      SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. “We are committed to developing superior vaccines that provide broader protection than what is available currently and to developing novel vaccines that target pathogens for which no approved vaccines exist,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.